Roche’s Vabysmo Advantage Over Eylea Hard To See In Latest Head-To-Head

Both Drugs Dosed Monthly

 
• By Andrew McConaghie
Eye Test
Roche is aiming to add to Vabysmo's existing approvals in wet age-related macular degeneration and diabetic macular edema (DME). • Source: Shutterstock

More from Clinical Trials

More from R&D